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Schistosomiasis is one of the most debilitating tropical diseases with the potential 
to cause morbidity and mortality in infected populations unless well controlled. 
Current control measures are limited to treatment with praziquantel. A rather 
alarming situation given i) the inability of the drug to directly target the pathogenic 
eggs, ii) the emergence of praziquantel-resistant schistosomes, iii) the 
persistence of tissue fibro-proliferative destruction caused by the trapped 
parasite eggs, even after treatment.  Intestinal and liver immunopathology are 
pathognomonic of schistosomiasis and generally result from the host inadequate 
Th2 and or Th17 responses to the egg-derived antigens. Failure to control these 
immune responses causes the most of the detriment to the infected host, 
highlighting the need for a better understanding of the regulatory mechanisms 
which might help prevent excessive immune responsiveness and the ensuing 
immunopathology.  
A Basic leucine zipper transcription factor ATF-like 2 (BATF2) which belongs to 
a family of transcription factors critical in the control of inflammatory responses 
has gained enormous momentum recently as a potential target to immune 
deregulation during cancer and infectious diseases. We reasoned that an 
eventual BATF2 influence on the host immune response during schistosomiasis 
might unveil its anti-disease potency and greatly facilitate the quest for a novel 
control strategy against the immunopathology during schistosomiasis. 
Addressing this in our present study, BATF2-deficient mice were used and 
characterized for immunological and physiological parameters during steady 
state and Schistosomiasis. Although the liver  showed a reduced pro-fibrotic 
response, there was a notable increase of several pro-fibrotic cytokines (TNF-α, 
IFN-ƴ, TGF-β and IL-13) Which further translated into an elevated level of 
granulomatous inflammation and fibrosis in the gut of S. mansoni infected BATF-
2-deficient mice when compared to the liver tissues of BATF2-deficient mice and 
both livers and intestines of infected littermate controls indicating that BATF2 
appears to have a tissue-specific role on the regulation of fibrogranulomatous 
inflammation during schistosomiasis. Therefore, BATF2 has a critical, and 
hitherto unappreciated, role in mediating the regulation of gut fibrogranulomatous 




1. Literature review: 
 
1.1. Schistosomiasis  
 
1.1.1. Schistosomiasis disease and the disease-causing agents/species 
 
Schistosomiasis also known as bilharzia or snail fever, is a prevalent disease 
that is caused by parasitic worms of the genus Schistosoma (Pedras, 1996) 
resulting in acute and chronic disease mainly carried by fresh water snails (Sabin 
Vaccine Institute, 2015; WHO, 2017). The species of the genus include 
Schistosoma mansoni (S. mansoni), Schistosoma japonicum and Schistosoma 
haematobium (S. haematobium) being the major causes of human morbidity and 
mortality (Pearce, 2002; Cavalcanti, 2015). The disease predominantly affects 
tropical and sub-tropical regions with the majority of people affected by the 
disease being in Africa (Sabin Vaccine Institute, 2015). Moreover, the infection 
rate of the disease is higher in children than in adults since they are more in 
contact with contaminated freshwater (Gryseels, 2016; WHO, 2017). 
Schistosomiasis is regarded as a disease of poverty and one of the most 
common parasitic diseases ranking second only to malaria (Sabin Vaccine 
Institute, 2015; WHO, 2016). S. mansoni is the most widespread of human-
infecting schistosomes developing a spectrum of symptoms, together with S. 
japonicum, which includes cercarial dermatitis and tissue inflammation within the 
liver and intestines of infected individuals, as well as severe hepatosplenic 
schistosomiasis (Hams, 2013).  
 
1.1.2. Life cycle of S. mansoni 
 
The lifecycle of the S. mansoni as shown in figure 1 (Dunne, 2005), involves two 
main hosts including humans and snails of the species biomphalaria glabrata. 
The parasite eggs that are released into fresh water hatch upon optimal 




snail intermediate host to infect. The miracidiae, once in a snail intermediate host, 
multiply and generate sporocysts which develop into larvae called cercariae 
(Centers for Disease Control and Prevention, 2012). The cercariae are released 
from the snails into fresh water ready to infect a human host. When they come 
into contact with a human, they attach and crawl along the skin looking for entry 
points such as sweat glands where they penetrate the skin - initiating an infection 
(Haas and Schmitt, 1982). The cercariae will shed their forked tail transforming 
into schistosomulae which will enter the vasculature and migrate to the 
mesenteric veins, where they mature into adult worms (Pearce, 2002; Wilson, 
2007; Centers for Disease Control and Prevention, 2012). The adult parasites 
can live up to 10 years or more in the mesenteric veins, releasing hundreds of 
eggs each day (Pearce, 2002). Some of the eggs are released back into the 
environment via faeces, while others get trapped in the microvasculature of the 
liver and the gut. At this point the eggs induce a vigorous granulomatous 
response that is characterized by the development of fibrosis and portal 
hypertension which are the primary causes of morbidity and mortality in infected 






Figure 1: Life cycle of Schistosoma mansoni (Dunne, 2005) 
 
 
1.1.3. Epidemiology (transmission and control of disease) of S. mansoni 
 
Schistosomiasis is mostly prevalent in tropical and sub-tropical regions, and 
affects mainly poor communities, especially agricultural and fishing populations, 
who do not have access to safe drinking water or adequate sanitation (WHO, 
2017). People, mostly from endemic areas, get infected with the parasites during 
routine agricultural, domestic, occupational, and recreational activities which 
provides the basis for exposure to contaminated water (WHO, 2017). Among the 




risk and show a high infection rate due to lack of hygiene and certain play habits 
which include swimming and or wading (Centers for Disease Control and 
Prevention, 2012; Gryseels, 2016; WHO, 2017). Women are also at high risk of 
infection from exposure to infested water given their domestic chores which 
include doing laundry in rivers. Tourist attraction sites/areas such the Nile valley 
in Sudan and Egypt also serve as high risk areas of infection by the parasites, 
especially the S. mansoni species (Centers for Disease Control and Prevention, 
2012). The S. mansoni are mainly distributed throughout Africa, South America 
(Brazil, Suriname, and Venezuela). The Caribbean islands of Dominican 
Republic, Guadeloupe, Martinique, and Saint Lucia have low infection rates. The 
increased risk of infection is mainly around areas of freshwaters such as lakes, 
rivers and small bodies of water (Centers for Disease Control and Prevention, 
2012; WHO, 2017). The disease reaches urban areas due to population 
movements which include tourists, facility transmission, and the need for water 
sources (WHO, 2017).  
 
1.1.4. Diagnosis of Schistosomiasis 
 
 The disease is mainly diagnosed through parasitological techniques that detects 
for the presence of parasite eggs in stool (S. mansoni) or urine (S. haematobium) 
specimens (van Dam, 2004; WHO, 2017). Although such techniques have 
limitations in that they include a high fluctuation in egg counts, one could easily 
misdiagnose low infections, and these techniques are usually time consuming 
(van Dam, 2004). The immunological techniques are also employed to diagnose 
the disease by detecting antigens, or antibodies raised against the parasite 
antigens in blood or urine (van Dam, 2004; WHO, 2017). These techniques have 









1.1.5. Disease complications and current estimates of burden 
 
Individuals infected with schistosomes develop a plethora of symptoms that can 
clustered depending on the species. The essential of symptoms associated with 
all schistosomiases is provided by a seminal review article of Ross and 
Collaborators (Ross et al., 2002). For the purpose of the present work, however, 
the emphasis is on the clinical features of infections caused by S. mansoni. 
Individuals affected by S. mansoni often develop a spectrum of symptoms which 
include cercarial dermatitis and tissue inflammation within the liver, and 
intestines. These can lead to a more severe hepatosplenic schistosomiasis 
(Hams, 2013). Previous studies have shown that the pathology observed during 
schistosomiasis is a result of an excessive or dysregulated inflammatory 
response to the parasite eggs that become trapped in various tissues (primarily 
liver and gut) of the infected individual (Hams, 2013). Schistosomiasis is 
characterized by two main clinical conditions termed acute schistosomiasis and 
chronic schistosomiasis (Pearce, 2002) which are mediated by different immune 
responses, as primarily gleaned from experimental murine studies and confirmed 
in human trials (Romagnani, 1992). Acute schistosomiasis mainly develops in 
individuals who are non-immune travellers with symptoms, such as fever, cough, 
muscle aches, and rash, appearing 2 to 12 weeks post exposure (Leshem, 2008; 
Centers for Disease Control and Prevention, 2012). In the case of chronic 
schistosomiasis, affected individuals display clinical symptoms such as 
abdominal pain, bloody diarrhoea or hematuria, anemia, splenomegaly and 
hepatomegaly (Centers for Disease Control and Prevention, 2012). In severe 
cases, the parasite eggs could pass through the blood brain barrier and cause 
seizures, paralysis, and or spinal cord inflammation (Centers for Disease Control 
and Prevention, 2012). With these alarming clinical conditions in infected 
individuals, it is estimated that more than 800 million individuals are at risk of 
infection from schistosomiasis globally, of which approximately 250 million are 
already infected (Sokolow, 2016; Loke et al., 2002; Caffrey, 2007; Chitsulo et al., 
2000; Hotez et al., 2006). The infection results in an estimated 280 000 deaths 





1.1.6. Schistosomiasis treatment and current control measures 
 
Treatment of the disease is mainly carried out with praziquantel which is reported 
to have a success cure rate of 65% to 90 % after a single treatment. 
Corticosteroids are also used as adjunct therapeutics in debilitating cases 
(Ahmed, 2017) However, the praziquantel does not protect against re-infection 
and besides the known anti-parasitic effect on adult schistosome worms, this 
reference drug is ineffective against developing schistosomula and does not 
directly target the pathogenic eggs (Olds, 2003). The drug might also become 
ineffective as recent reports have now surfaced to suggest that clinical 
schistosomes isolated in some hyperendemic area are becoming more resistant 
to Praziquantel (Vale, 2017; Melman, 2009; Ishmail, 1999).   
 
1.2. Immune polarization and the control of schistosomiasis pathology 
 
1.2.1. Immune cell development and selection 
 
Dendritic cells play an essential role linking innate and adaptive immune 
responses during infections or encounter with antigens allowing naïve T cells to 
differentiate into antigen specific effector T cells (Oh, 2015; Banchereau, 1998). 
When the dendritic cells recognise an antigen through pattern recognition 
receptor (PRR) they initiate phagocytosis leading to processing and loading of 
the processed antigen on major histocompatibility complex presented on the 
surface of the cells (Hossain, 2013; Medzhitov, 2007). The MHC-peptide 
complex is further recognised in thymus by naïve T cells which express T cell 
receptor (TCR) allowing differentiation into a protective CD4+ or CD8+ T cell 
response against the antigen presented by MCHI or MCHII respectively (Oh, 
2015). Selection of T cells in the thymus is dependent on both foreign and self-
antigens which helps mediate adequate immune responses that either clears off 
the foreign antigens via effector T cells, or tolerates via regulatory T cells, the 





In some cases tolerogenic/suppressive immune response is also mounted 
toward foreign antigens (Oh, 2015), and this is mainly in tissues such the 
intestine which is constantly exposed to food and commensal antigens (Oh, 
2015; Tomasello, 2013). The immune response in the intestine has developed a 
complex system that allows discrimination of commensal microbes and 
pathogens which could trigger complications such as inflammatory bowel or 
coeliac disease (British Society for Immunology, 2017). The intestinal immune 
system is comprised of intestinal epithelial lymphocytes (IEL), intra epithelial 
lymphocytes (ILF), and tissue-specific organised lymphoid structures (Peyer’s 
patches, mesenteric lymph nodes, cryptopatches and isolated lymphoid follicles) 
which  all work together to help the intestinal tissue to take up nutrients and fluids 
while discriminating against pathogenic antigens (Tomasello, 2013)      
 
1.2.2. Host response during the initial phase of infection 
 
During early stage of infection (3 – 5 weeks), migrating immature parasites drive 
a dominant type 1 immune response as judged by the expansion of T helper (Th) 
1 cells, classically activated macrophages (M1) and  the release of cytokines 
such as Tumour necrosis factor (TNF), interferon gamma (IFN-ƴ) (de Jesus, 
2002; Wynn, 1993; Bogen, 1995). 
 
1.2.3. Host response during the acute phase of infection 
 
As the parasite development continues and results in the production of eggs by 
female adults, a type 2 dominated acute response is mounted between 6 to 10 
weeks post infection (Bogen, 1995; Fallon, 2007; Wilson, 2007). The acute 
response is characterized by type 2 granulomatous inflammation which results 
from the accumulation of CD4+ T helper 2 cells, eosinophils, and alternatively 
activated macrophage (M2) around the eggs lodged in tissues, and the release 
of type 2 effector cytokines such as IL-4, IL-5, and IL-13 (Fallon, 2007; Pearce, 




antigen presenting cells (APC) such as dendritic cells interact with the antigens, 
process and present them to CD4+ T cells which will initiate a protective type 2 
inflammatory response (Rutitzky, 2007; Pearce, 2002; Hammerich, 2010). In 
most cases the CD11b+ dendritic cells initiate the activation of a more protective 
CD4+ T cell response during s. mansoni infection, that is polarized into a Th2 
phenotype, characterised by the production of IL-4, IL-5, and IL-13, and is driven 
by signal transducer and activation of transcription factor (STAT) 6, GATA-3 and 
IL-4 (Rutitzky, 2007; Hammerich, 2010; Mayer, 2017). In the event of this 
protective Th2 response, a type 1 CD8+ T cell response is also concurrently 
initiated to regulate the development of exacerbated Th2 response (Pedras-
Vasconcelos, 1996), and this response was recently shown to be driven by 
BATF3-driven CD8+ dendritic cells through constitutive expression of IL-12 
(Everts, 2015). 
 
However, in severe cases of schistosomiasis, the CD4+ T cells are more 
polarized into a pathogenic Th17 phenotype that is driven by TGF-β and IL-23 
and is characterized by expression of orphan nuclear receptor RORƴt as well as 
production of IL-17 (Rutitzky, 2007; Hammerich, 2010). It has previously been 
suggested that the mechanism in which the Th17 cells cause a severe pathology 
in the case of Schistosomiasis is through the recruitment of granulocytes such 
as eosinophils (Rutitzky, 2007). It is therefore, imperative that both type 1 and 
type 2 immune responses are co-actively initiated to mount an equilibrated, 
protective and well controlled immune response with no or less pathological 
consequences during acute Schistosomiasis. To achieve this, a more detailed 
understanding of the mechanisms and factors contributing to a well-controlled 
protective immune response, is required during acute schistosomiasis.   
 
1.2.4. Host response during the chronic phase of infection 
 
Following the acute phase is a more regulatory response starting as from week 
10 post-infection onwards (Fallon, 2007; Pearce. 2002). In this phase, the type-
2 inflammatory response against the trapped parasite eggs is mitigated and the 




(Schmiedel, 2015; Pearce, 2002).  Additionally, an intrinsic Th2 cell hypo-
responsiveness is also suggested to contribute to the establishment of chronicity 
during schistosomiasis (Yang, 2009; Wilson, 2007) further illustrating the rather 
complex nature of the regulatory processes that dictate the establishment of a 
minimally pathogenic chronic phase during schistosomiasis (Pearce, 2002; 
Vasconcelos, 1996). 
 
1.2.5. Current evidences of the therapeutic value of altering immune 
polarization during schistosomiasis. 
 
Two major immune defects account for the majority of the morbidities associated 
with schistosomiasis. These are: i) the host inability to mount an appropriate 
inflammatory response to entrap within a robust granuloma the released toxins 
from the parasite eggs and ii) the host inadequate regulatory response to tame 
the fierce anti-egg response elicited during acute schistosomiasis as the infection 
progresses towards equilibrium (Ramadan, 2013; Wang, 2015). These failures 
usually result in heightened tissue pathology and eventually premature death as 
extensively reported in murine models (Herbert, 2004; Leeto, 2006). With no 
vaccine and a rather limited, albeit still efficacious praziquantel-based 
chemotherapy available, an accumulating number of reports have now 
successfully addressed the possibility of ameliorating tissue pathology thus 
morbidity by altering the host immune response during experimental 
schistosomiasis (Ramalingam, 2016).  In these studies, a striking ability to 
reduce excessive tissue fibrosis thus schistosomiasis-driven pathology was 
achieved by either blocking IL-13 alone (Mentink-Kane, 2004), dually blocking 
IL-13 and IFN-g (Chiaramonte, 2003) or completely interrupting IL-13 and IL-4 









1.3. A host factor regulating immune polarization: the basic leucine 
zipper ATF-like (BATF)-2 transcription factor 
 
1.3.1. Definition of the BATF family of transcription factors 
 
Basic leucine zipper transcription factor ATF-like (BATF) 2 belongs to a family of 
transcription factors called BATF family which in turn belongs to a family of 
transcription factors called activator protein 1 (AP-1) (Murphy, 2013). The BATF 
family comprises of BATF, BATF2, and BATF3, which play a role in the 
development and regulation of the immune cells.  
 
1.3.2. Role of BATF family members in immunity  
 
BATF and BATF3 have been shown to be involved in the development and 
regulation of B cells, dendritic cells, T cells, and macrophages (Murphy, 2013). 
The transcription factors are characterized by α-helical basic leucine zipper 
(bZIP) structures. The structures contain a basic DNA binding region and a 
leucine zipper domain which allows members of this family to form heterodimers 
with other AP-1 family members such as JUN proteins and non AP-1 members 
including interferon-regulatory factor 1 (IRF1), IRF4, and IRF8 (Murphy, 2013).  
i) BATF is one of the extensively studied transcription factors that is mainly 
involved in development and regulation of immune cells such as Th9, Th17, 
follicular helper T (Tfh) cell, adipose tissue-resident regulatory T cells and 
effector CD8+ T cells (Guler, 2013). The transcription factor also regulates the 
immunoglobulin class switching in B cells as well as the expression of GATA3 
and effector factors (IL-4, IL-10, CTLA4) in Th2 cells (Betz, 2010;  Ise, 2011). 
Studies have demonstrated the transcription factor as a central modulator of 
peripheral and humoral hallmarks of type 2 immune response during 
anthelminthic immunity which helps in establishment of an adequate type 2 
immunity during infection (Bao, 2016).   
Ii) On the other hand, BATF3 is reported to be involved in the development of 
CD8α + dendritic cells and both BATF and BATF2 can compensate for its 




iii) BATF2, unlike the other members of BATF family, is being increasingly 
studied only of recent. Besides its initial role elegantly defined in the 
compensation for BATF3 deficiency during the development of CD8α + dendritic 
cells (Hildner, 2008), evidences have now been provided for the massive 
induction of BATF2 in type-1 polarized macrophages to sustain inflammatory 
responses in vitro during mycobacterial infection (Roy, 2015). Furthermore 
BATF2 was also shown to suppress Th17-driven responsesthrough the 
suppression of IL-23 production by dendritic cells during experimental 
trypanosomiasis (Kitada, 2017).  
  
1.3.3. Role of BATF family during disease  
 
The BATF family members are shown to play crucial roles in coordinating the 
immune system activities which are critical in autoimmunity, inflammation and 
the host response to pathogens (Muphy, 2013; Roy, 2015, Hildner, 2008) with 
the BATF being identified as a central modulator of peripheral and humoral 
hallmarks of type-2 immunity during anthelminthic immunity (Bao, 2016). The 
BATF3 on the other hand was reported to drive Th1 immunity through the 
production of IL-12 to protect against Leishmania major or to suppress helminth-
driven type-2 immunity (Mart´ınez-L´opez, 2015; Everts, 2015). 
The BATF2 was first assigned a role in the development of CD8+ dendritic cells, 
and was later shown to also induce type-1 inflammatory responses in classically 
activated macrophages during mycobacterium tuberculosis infection (Roy, 
2015). A recent study by Kitada et al., has reported on the role of BATF2 to inhibit 
immuno-pathological Th17 response during Trypanosoma cruzi, through the 
suppression of production of IL-23 (Kitada et al., 2017).  
Therefore, BATF family members in general, and BATF2 in particular, appear to 
be considerably relevant for the coordination and regulation of inflammatory 
responses during disease and as such, attractive targets for the immune-
alteration of immunopathological processes they might govern in disease, a 
strategy that has already gathered a heavy momentum in the context of cancer 




1.4. Problem statement and justification of the present project 
 
BATF2, a now increasingly reported host inflammatory regulator in cancer and 
infectious diseases (Roy, 2015; Guler, 2015; Ma, 2011) is still poorly studied in 
the context of helminth infections. The present study, therefore attempted to 
explore further the role of this transcription factor during Schistosomiasis and 
provide a better understanding on how the targeting of this factor could be 
exploited to improve the current disease control measures given its potential to 
regulate helminth driven pathology.  
 
1.5. Hypothesis  
 
Given the reported role of BATF2 in the induction of Th1 and suppression of Th17 
responses during infections, we hypothesized that BATF2 deficiency may 
promote Th2 and Th17 responses during acute schistosomiasis and result in 
morbidity and possibly mortality in S. mansoni-infected mice. 
 
1.5. Aim and objectives of the study 
 





To achieve our aim, we set forth  
- To measure the changes in expression rates of BATF2 in the liver and intestinal 
tissues of mice following S. mansoni infection. 
- To characterize a BATF2 deficient mouse model. 
- To characterize the immune and pathological responses that associate with the 
absence of BATF2 during acute infection with Schistosoma mansoni. 
- To determine the survival rate of BATF2 deficient mice during infection with 




2. Materials and methods 
 
2.1. Ethics statement 
 
All the experiments performed were conducted in accordance with the Animal 
Research Ethics Committee of South African National Standard (SANS 
10386:2008) and University of Cape Town, South Africa for practice on animal 
procedures. The study protocols (Permit numbers: 014/003 and 016/027) were 
approved by the Animal Ethics Committee, Faculty of Health Sciences, 
University of Cape Town (Cape Town, South Africa). 
 
2.2. Generation, genotyping and characterization of BATF2 deficient 
mice 
 
BATF2 deficient mice were generated from the 129 background mice which 
demonstrate a skewing of the immune response towards a more Th2 responses 
ideal for studying helminth infections, than the C57BL/6 which demonstrate 
skewing towards Th1 responses (O’Neill et. al., 2000). The 129 mice are 
generally poor learners and thus cannot be utilized for behavioural studies 
(Rivera et. al., 2008), but unlike with the C57BL/6 mice, the 129 are not limited 
to certain immunological questions such as the development of tumor unlike the 
C57BL/6 mice which are resistant to tumor development (O’Neill et. al., 2000).   
 
Wild type (WT) and BATF2-/- 129SvEv mice were generated using homologous 
recombination (figure 2) and purchased from The Jackson Laboratory. Briefly: A 
targeting vector was initially designed with a gene containing a loxP site, an frt 
site, a neomycin resistance (neo) cassette in reverse orientation, a second loxP 
and frt sites. The gene was used, from 5’ to 3’, to replace exons 1-2 of the basic 
leucine zipper transcription factor, ATF-like 2 (BATF2). The new recombinant 
construct was then electroporated into 129S6/SvEvTac-derived EDJ22 
embryonic stem (ES) cells. ES cells with the new gene construct were then 
injected into blastocysts resulting in chimeric mice. The male chimeric mice were 




which were later inbred for at least one generation to establish the colony. All 
mice are housed under quarantine conditions in the University of Cape Town 
animal facility. Figure 2. Generation of a targeting construct for BATF2 mice by 
homologous recombination.  
     
  
Figure 2: Generation of a targeting construct for BATF2 mice by homologous 
recombination. 
 
Mice were genotyped using PCR to determine whether the BATF2 exons 1 and 
2 were removed from the genome of BATF2-/- mice using the following primers: 
Forward primer 5’ 3’, and reverse primer BATF2 P1 (5'-ACC CTC CAC CAT CCT 
TCT TC), BATF2 P2 (5'- GAC TGG TCT GCA GTG TGA GC), BATF2 P3 (5'- 
CCA GCT CAT TCC TCC CAC T)..  
 
 
2.3. Maintenance of S. mansoni life cycle 
Biomphalaria glabrata snails together with BALB/c female mice were used to 
expand and maintain the S. mansoni parasites which were maintained and 





2.4. Experimental murine infection with S. mansoni  
 
2.4.1. Acute infection: Identifying the role of BATF2 during acute infection 
of S. mansoni.  
A total of 32 mice were used for the experiment. Sixteen wild type (BATF2+/+) 
and 16 (BATF2-/-) knockout mice, both female and male ranging between 7 - 12 
weeks old, were percutaneously infected with 100 live cercariae of S. mansoni 
obtained from the Biomphalaria glabrata snails. The mice were monitored 1-2 
times a day, weighed weekly and recorded for a period of 7 weeks. 
Approximately 500 – 600 µl of blood was collected using cardiac puncture, and 
organ weights which include liver, spleen, heart, and lung were measured 
recorded and collected. Abdomens of euthanized mice were exposed to observe 
and capture any physiological damages that could possibly result in experimental 
end-point of the mice. 
 
 
Figure 3: Acute infection protocol to be followed 
 
 
2.4.2. Mortality infection: Survival rate of BATF2 deficient mice post S. 
mansoni infection.  
 
A total of 36 mice were used for the experiment. Eighteen wild type (BATF2+/+) 
and 18 (BATF2-/-) mice, both female and male ranging between 6 - 8 weeks old, 
were percutaneously infected with 80 live cercariae of S. mansoni obtained from 
the Biomphalaria glabrata snails. The mice were monitored for mortality 1-2 times 




The experimental end point of the mice infected with S. mansoni parasites were 
reached when each mouse showed the following symptoms: Loss of weight up 
to 20% from its original body weight, highly reduced activity indicating discomfort, 
uneven and sticking out of fur, inability to open eyes wide, and loss of strength 
as evidenced from inability to grip on a metal bar cage.  
Final body weight was recorded and approximately 500 – 600 µl of blood was 
collected using cardiac puncture. Abdomen of euthanized mice were exposed to 
observe and capture any physiological damages that could possibly result in 
experimental end-point of the mice. 
 
 
Figure 4: Mortality protocol to be followed. 
 
 
2.5. Assessing BATF2 gene expression levels in tissues 
 
2.5.1. RNA extraction 
 
RNA was extracted by first homogenizing tissue samples and then used RNA 
elute Column protocol (Qiagen, USA) to carry out the extraction. The samples 
were vigorously mixed using a vortex for 1 minute and 200 µl of chloroform was 
added in each sample containing 1ml of Qiazol. The samples were mixed 
vigorously by shaking up and down then incubated for 3 minutes at room 
temperature. Again the samples were vigorously shook and then centrifuged for 
15 minutes at 10 000 revolutions per minute (rpm) in a 40C microfuge. The 
colourless upper aqueous layer was then transferred into a new tube and 1ml of 
70% ethanol was added to the lysate and mixed by pipetting.  Seven microliters 




placed in 2ml collection tube. The samples were then centrifuged for 15 seconds 
at 10 000 rpm and the flow-through was discarded. Seven hundred microliters of 
RW1 buffer was added to the RNeasy spin column centrifuged for 15 seconds at 
10 000 rpm. The flow through was discarded removing all residues of the flow-
through and 500µl of RPE buffer was added to the RNeasy spin column then 
centrifuged for 15 seconds at 10 000 rpm. Another 500µl of RPE buffer was 
added was added to the spin column and centrifuged for 2 minutes at 10 000 
rpm. The RNeasy spin column was then transferred into a new 2ml collection 
tube and centrifuged for the tubes for 1 minute at full speed. The RNeasy spin 
column was transferred again, into a new 1.5ml collection tube and then 
centrifuged for 1 minute at 10 000 rpm with the flow-through containing RNA 
samples needed for further analysis. The presence of RNA was confirmed by 
measuring of samples using a nanodrop ND1000 (Thermo Scientific, USA) and 
by loading a preheated mixture of 15µl of sample and 1µl of 1x loading buffer in 
a 1.5% agarose gel composed of 1.5g of agarose powder in 100ml of 0.5X TBE 
buffer and heated for 5 minutes, plus 10µl of Sybr safe DNA stain (Thermo 
Scientific, USA). The gel was allowed to run for 40 minutes using 150V of voltage.     
 
2.5.2. cDNA synthesis 
 
The cDNA Synthesis was carried out to reverse transcribe the extracted unstable 
RNA into a more stable cDNA molecule. An amount of 10µl of each sample was 
added into correctly labelled sterile, nuclease-free thin-walled PCR tubes. One 
microliters of Anchored-oligo (dT) 18 primer (50 pmol/µl) plus 2µl of Random 
hexamor primer (600pmol/µl) were added to the samples and mixed them. The 
template-primer mixture was then denatured by heating the tubes for 10 minutes 
at 650C in a thermal block cycler (BioRad PTC-100, USA). The tubes were 
immediately cooled on ice. A first strand synthesis cocktail composed of 1X 
Transcriptor Reverse Transcriptase reaction buffer (8mM MgCl2), plus 20 units 
of protector RNase Inhibitor (40U/µl), plus 1mM of each of the deoxy-nucleotides, 
and 10 units of transcriptor reverse transcriptase, was added to the tubes 
containing the RNA samples and mixed gently. The tubes were then placed in 
the thermal block with a heated lid and the incubated the reactions using the 




and the PCR reaction was then stopped by placing the tubes on ice for 5 minutes 
and then stored in -800C freezer until further analysis. 
 
2.5.3. Quantitative Polymerase Chain Reaction (qPCR) 
Quantitative polymerase chain reaction was carried out on the cDNA samples 
obtained above to measure levels of target gene expression in liver and gut 
tissues.    
 
2.6. Single Cell preparations   
 
2.6.1. Single cell preparations from Mesenteric Lymph Nodes and 
Thymus 
 
Mesenteric Lymph Nodes and Thymus were collected in 2ml Eppendorf tubes 
containing 1ml of Iscove’s Modified Dulbecco’s Medium (IMDM) (Gibco, USA) 
supplemented with 10% heat inactivated Fetal Bovine Serum (iFBS) (Roche 
Diagnostics, Germany) and 0.5% Penicillin-Streptomycin (Pen-strep) (Gibco, 
USA). Each sample was teased through a 70µm sieve (Thermo Scientific, USA) 
on a petri-dish. The solution was further collected and sieved through 40µm sieve 
into a new labelled 50µl tube, and then topped up to 5ml total solution. The 
samples were centrifuged for 10 minutes at 1200 rpm and the supernatant was 
discarded, then re-suspended the samples in 5ml medium (IMDM supplemented 
with 10% iFBS and 0.5% Pen-strep). The cells were then counted using 2% 
trypan blue using 1 in 20 dilution. 
 
2.7. Single cell preparations from Liver and gut 
 
Liver samples were collected in 15ml tubes containing ice cold 5ml medium 
(IMDM supplemented with 10% iFBS and 0.5% Pen-strep. The samples were 
placed on a petri-dish and chopped into small pieces then placed into 15ml tube 
containing 5ml digestion buffer (IMDM supplemented with 5% iFBS, plus 50 U/ml 
Collagenase I or II (Sigma, USA), plus 13µg/ml DNase (Thermo Scientific, USA). 




minutes. After the incubation, they were sieved through a 100µm sieve on a petri-
dish and sieved again through a 70µm sieve into a new 50ml tube. The samples 
were centrifuged for 10 minutes at 1200 rpm in a 40C and then discarded the 
supernatant. Three millilitre of PBS + 3% foetal calf serum (FCS) was used to re-
suspend the samples and then added 1.7ml of isotonic percoll (9ml percoll + 1ml 
of 10X PBS), and then mixed thoroughly by inverting the tubes gently. The tubes 
were centrifuged for 10 minutes at 500g in 40C without brakes. The supernatant 
was carefully removed from the tubes and 5ml of red blood cell (RBC) lysis buffer 
was used to re-suspend the samples, then incubated for 10 minutes at room 
temperature. Five millilitre of medium (IMDM supplemented with 10% iFBS and 
0.5% Pen-strep) was added to the solutions and then centrifuged for 10 minutes 
at 1200 rpm in 40C. The supernatant was carefully removed and the samples 
were re-suspended in 1ml of medium (IMDM supplemented with 10% iFBS and 
0.5% Pen-strep). The cells were counted using 2% trypan blue using 1 in 2 
dilution. 
 
2.8. Single cell preparations from Spleen 
 
Spleen samples were collected in 2ml Eppendorf tubes containing 1ml of 
medium (IMDM supplemented with 10% iFBS and 0.5% Pen-strep). Each 
sample was teased through a 100µm sieve (Thermo Scientific, USA) on a petri-
dish and was further sieved through a 70µm sieve into a new 50ml tube. The 
samples were centrifuged for 10 minutes at 1200 rpm and the supernatant was 
discarded then re-suspended the samples in a 5ml red blood cell (RBC) lysis 
buffer (8.24g Ammonium chloride (NH4Cl) + 0.037g EDTA + 1g NaHCO3 + 1 litre 
of 1X PBS) and incubated for 10 minutes at room temperature. After the 
incubation, 3ml of medium was added and the samples were centrifuged for 10 
minutes at 1200 rpm again. The supernatant was discarded then re-suspended 
the samples with 5ml medium and sieved through a 40µm sieve into a new 50ml 
tube and centrifuged for 10 minutes at 1200 rpm. The cells were counted using 






2.9. Single cell preparations from Lung 
 
Spleen samples were first placed on a petri-dish and chopped into small pieces 
and collected in a 15ml tubes containing 5ml of digestion medium (IMDM 
supplemented with 5% iFBS, plus 50 U/ml Collagenase I (Gibco), plus 13µg/ml 
DNase I. The samples were incubated for 30 minutes at 370C. After the 
incubation, the samples were teased through a 100µm sieve on a petri-dish. The 
samples were further sieved through a 70µm sieve into a new 50ml tube and 
then centrifuged for 10 minutes at 1200 rpm. The cells were then re-suspended 
in a 5ml RBC lysis buffer and incubated for 5 minutes at room temperature. Three 
millilitre was added after the incubation and then centrifuged for 5 minutes at 
1200 rpm. The samples were then re-suspended in 1ml of medium and sieved 
through a 40µm sieve into a new 50ml tube, then centrifuged for 10 minutes at 
1200 rpm. The cells were counted using 2% trypan blue using 1 in 10 dilution. 
 
 
2.10. Antibodies and Flow cytometry Analysis 
 
2.10.1. Surface staining 
 
A total of 2 000 000 cells per 200µl of medium (IMDM supplemented with 10% 
iFBS and 0.5% Pen-strep) from each of the samples was added into a V bottom 
plate (Nalge Nunc International, USA) and centrifuged for 5 minutes at 1500 rpm. 
The staining antibody cocktail was prepared containing facs buffer (% BSA and 
1X PBS buffer), 2% heat inactivated rat serum (iRS), 1% FcƴRIII plus the 
following combination of surface antibody markers also shown in Appendix 1.  
 
CD45 (PE), Siglec-F (APC), F4/80 (PE-Cy7), 7AAD (PerCp Cy5.5), CD4 
(FITCS), CD11b (V450), CD11c (A700), Ly6G (APC-Cy7), CD8 (V500). 
And  
Lin (PE), ICOS (APC), 7AAD (PerCp Cy5.5), T1ST2 (FITCS), CD45 (Texas red) 
 
 After centrifugation, the supernatant was discarded from the plate gently and the 




covered with a foil and incubated for 30 minutes in 40C fridge. Two hundred 
microliters of Facs buffer was added into the samples and centrifuged for 5 
minutes at 1500 rpm. The supernatant was discarded and the samples were re-
suspended in 100µl of Facs buffer, then transferred into facs tubes for analysis 
on LSR Fortessa (BD Immunocytometry system, USA). The samples were 
analysed using FlowJo software (Treestar, USA). 
 
2.10.2. Intra-cellular staining 
 
2.10.2.1. Ex-vivo re-stimulation 
 
A mixture containing 500µl of medium (IMDM supplemented with 10% iFBS and 
0.5% Pen-strep), 2.5µl of 50ng/ml Phorbol 12-myristate 13-acetate (PMA), 2.5µl 
of 250ng/ml Ionomycin, and 2µl of 200µM Monensin were prepared. Ten 
microliters of the mixture was added into the wells of a new sterile flat bottom 
plate (Nalge Nunc International, USA) and about 200µl of the cell suspension 
containing 2x106 cells was also added to the mixture in the plate. The plate was 




The re-stimulated cell suspension (≥200µl) was transferred from the flat bottom 
plate and into a new sterile V bottom plate and then centrifuged for 5 minutes at 
1500rpm. The supernatant was gently discarded and added 50µl of the 1st 
staining antibody cocktail containing facs buffer (% BSA and 1X PBS buffer), 2% 
heat inactivated rat serum (iRS), 1% FcƴRIII plus the following combination of 
antibody markers also shown in Appendix 1. CD4 (FITCS), CD11b (V450), CD3 
(A700), CD8 (V500). CD45 (Texas red). 
 
The plates were covered with a foil and incubated for 30 minutes at 40C fridge. 
Two hundred microliters of Facs buffer was added into the samples and 
centrifuged for 5 minutes at 1500 rpm. The supernatant was discarded and the 
samples were re-suspended in 100µl ice-cold 1x PBS buffer. Then 100µl of 4% 




for 60 minutes. After incubation, 200µl of ice-cold 1x PBS buffer was added. The 
samples were then centrifuged for 5 minutes at 1500 rpm and gently discarded 
the supernatant. The samples were re-suspended in 200µl of permeabilization 
buffer. Again the samples were incubated on ice in dark for 60 minutes and then 
centrifuged for 5 minutes at 1500 rpm. They were then re-suspended in 50µl of 
staining cytokine cocktail containing 1x 2% heat inactivated rat serum (iRBS), 
1% FcƴRIII plus the following combination of antibody markers also shown in 
Appendix 1.  
 
IL-5 (PE) , IL-13 (PE-Cy7), IL-4 (PerCp Cy5.5), IL-17 (APC-Cy7), 
 
The samples were incubated on ice in dark for 60 minutes and then added 200µl 
of permeabilization buffer. The samples were centrifuged for 5 minutes at 1500 
rpm and then re-suspended in 100µl of facs buffer and transferred into facs tubes 
for analysis on LSR Fortessa. 
 
 
2.11. Ex-vivo re-stimulation for cytokine analysis 
 
All the reagents used in this experiment were sterile and the work was carried 
out in a sterile environment. One flat bottom plate (Nalge Nunc International, 
USA) was coated with 50µl of medium (IMDM supplemented with 10% iFBS and 
0.5% Pen-strep) containing 20µg/ml anti-CD3 and incubated for 2 hours in a 
370C incubator. After incubation, the supernatant was gently removed and 100µl 
of cell suspension containing 106 cells was added. In another flat bottom plate, 
100µl of 20µg/ml S. mansoni soluble egg antigen (SEA) dissolved in medium 
(IMDM supplemented with 10% iFBS and 0.5% Pen-strep) was added together 
with 100µl of cell suspension containing 106 cells. In a 3rd plate, 100µl of medium 
(IMDM supplemented with 10% iFBS and 0.5% Pen-strep) was added together 
with 100µl of cell suspension containing 106 cells. The three plates were 







2.12. Preparation of Tissue homogenates  
 
2.12.1. Liver and gut 
 
The samples were thawed on ice and 500µl of extraction buffer (1X PBS buffer 
with 1:100 dilution of protease inhibitor, and 0.1% Tween) was added to each of 
the samples. The samples were then homogenized using 5mm stainless steel 
bead for 5 minutes with break intervals after each 1 minute (5x 1 minute) allowing 
the samples to be completely homogenized. Another 500µl of the extraction 
buffer was added and the samples were centrifuged for 5 minutes at 4800 rpm 
in a 40C. The supernatant was then transferred into new labelled 2ml Eppendorf 
tubes and the protein content of each sample was measure using BCA assay 
(Thermo Scientific, USA) then stored in -800C until they were needed for further 
analysis. BCA assay was carried out according to manufacturer’s instructions to 
determine protein content (Thermo Scientific, USA. Catalog number 23225). 
 
 
2.13. Serum collection from whole blood 
 
The blood samples collected in blood collection tubes (Microtainer, BD, USA) 
were centrifuged for 15 minutes at 8000 revolutions per minute (rpm) to separate 
out the serum from whole blood and stored in -800C freezer until needed.  
 
 
2.14. Enzyme-Linked Immunosorbent Assay (ELISA) Analysis 
 
2.14.1. Cytokine analysis 
 
Cytokine responses were measured in serum, MLN stimulated either with 
20µg/ml of SEA or 20µg/ml of anti CD3, liver & gut homogenates from non-
infected and infected mice. Ninety six well plates (Nalge Nunc International, 




interest. The capture antibodies diluted in 1X PBS buffer were used - Refer to 
Appendix 2. 
 
The plates were incubated overnight in 40C fridge, and then washed with wash 
buffer (20g KCl, 20g KH2HPO4.2H2O, 800g NaCl, 50ml Tween-20, dissolved in 
5 litre, then diluted 1:20 in ddH2O) 3 times. The plates were blocked with 200µl 
of 2% milk powder then incubated for 2 hours in 370C. The plates were washed 
again with wash buffer 5 times and then added 50µl of samples together with 
recombinant standards for each cytokine tested. In the case of TGF-β, 48µl of 
samples plus 2µl of 1M HCl pH 3 and left to incubate for 1 hour in 40C. The 
reaction was stopped by adding 2µl of 1M of NaOH. All the plates were then 
incubated overnight in 40C. The recombinant proteins were used as standards - 
Refer to Appendix 2. 
 
After overnight incubation, the plates were washed again in wash buffer 5 times. 
Secondary biotinylated antibodies were then added to the appropriate plates for 
each of the test cytokines and incubated the plates for 2 hours in 370C. The 
plates were then washed 5 times using wash buffer and then added strep-avidin 
substrate conjugated with either alkaline phosphatase (AP) in 1/1000 dilution. 
The plates were incubated for 1 hour in 370C and then washed the plates again 
5 times using wash buffer. The plates were then developed by adding 1mg/ml of 
4 Nitrophenyl phosphate disodium salt hexahydrate (PNP) (Merck, Germany) 
diluted in AP substrate buffer into each well of the plates. The plates were again 
incubated for 10 minutes in 370C to allow for colour development in positive 
samples, and the optical density (OD) was measured on a VERSAmax 
microplate reader (Molecular devices, USA).  
 
 
2.14.2. Antibody analysis 
 
Antibody response was measured in blood serum samples collected from non-
infected and infected mice. The 96 well plates (Nalge Nunc International, USA) 




3 times using wash buffer and then blocked with 2% milk powder for 2 hours in 
370C. The plates were washed 5 times and serum samples were then added in 
a 10-fold dilution series. In the case of IgE, the samples were not diluted and the 
standard for the antibody was also included. The plates were then incubated 
overnight in 40C then washed 5 times using wash buffer. The plates were 
incubated for 2 hours in 370C with phosphatase-conjugated secondary detection 
antibodies for IgE. The plates were then developed using 1mg/ml of 4 
Nitrophenylphosphate (PNP) (Sigma-Aldrich, Germany) diluted in AP substrate 
buffer and incubated for 10 minutes in 370C. The OD was measured on a 
VERSAmax microplate reader (Molecular devices, USA). 
 
2.15. Quantification of liver enzymes in the serum ALT and AST analysis 
 
Serum samples were diluted by 1:20 in sterile 0.9% Saline solution and then 
submitted to the National health Laboratory Services for further analysis.  
  
 
2.16. Hydroxyproline Assay 
 
The hydroxylproline content was measured in liver and gut tissues collected from 
non-infected and infected mice. The tissue were first weighed and then 
transferred into clean glass screw cap tubes containing 5ml of 6M HCl and 
incubated overnight at 1100C incubator. The samples were topped up to 10ml by 
adding 5ml of double distilled water (dH2O) and then mixed by vortex. Two 
millilitre of each sample was filtered through Whitman No.1 filter paper (Sigma-
Aldrich, Germany) into new labelled 15ml falcon tubes. One drop of 1% 
phenolphthalein in ethanol was added into each of the tubes containing 2ml 
filtrate. A few drops of 10M NaOH were added into each filtrate sample until a 
colour change from light brown to pink was observed. A few more drops of 3M 
HCl were added to titrate the samples back to light brown and then topped up to 
4ml using dH2O. From each of the samples, 200µl was transferred into new 15ml 
falcon tubes and the OH-proline standards were prepared in a 2-fold dilution 




isopropanol was added and were mixed using vortex. Two hundred microliters of 
solution A was added into each tube and mixed, then incubated at room 
temperature for 10 minutes. Two and a half millilitres of solution B was added 
into the samples and mixed by vortex then incubated for 25 minutes in 600C 
water bath. The samples were immediately cooled in ice cold water then 
transferred 200µl of each of the samples into 96 well plates (Nalge Nunc 
International, USA). The samples’ OD was read using VERSAmax microplate 





Tissue samples (Liver and Gut) were fixed in neutral buffered formalin and 
processed, and about 5µm sections were stained with hematoxylin and eosin 
(H&E) or Chromotrope aniline blue (CAB). The diameters of each granuloma 
containing a single egg were measured using a computerized morphometry 
analysis program. The egg diameter were then subtracted from the diameter of 
the whole granuloma. A total of 100 granulomas per group of mice were 
measured for analysis. Tissue samples (Liver and Gut) fixed in neutral buffered 
formalin and processed were also stained with Chromotrope aniline blue (CAB) 
in order to measure fibrosis. 
 
2.18. Parasitaemia/egg burden determination. 
 
Tissue samples (Liver, Lung, and Gut) collected were processed for egg burden 
analysis. Briefly, the samples were incubated in 15ml tubes containing 5ml of 5% 
potassium hydroxide (KOH) overnight in a 370C incubator. The samples were 
then centrifuged for 10 minutes at 2000 revolutions per minute (rpm) and 3 ml of 
supernatant were discarded. The remaining supernatant was re-suspended 
using a vortex for 15 seconds and the 50µl of the sample was viewed under a 






2.19. Statistical analysis 
 
The values presented in this work are shown as mean ± SEM and significant 
differences were determined using the unpaired one or two--‐tailed Student’s t--‐







3.1. BATF2 sustained/ increased expression in egg-harbouring tissues 
during experimental schistosomiasis. 
 
The study initially assessed the expression of BATF2 at homeostasis in liver and 
intestinal tissues, and also assessed how Schistosomiasis infection alters the 
expression of this transcription factor in these organs given the preferential, if not 
exclusive retention of S. mansoni eggs in these tissues. In order to asses this, 
RNA was isolated from livers and guts of naïve and S. mansoni infected wild type 
(129SvEv) mice and reversed transcribed into cDNA. The BATF2 expression 
was then quantified by qPCR with HPRT primers as housekeeping gene. The 
expression of BATF2 was considerably higher in the liver when compared to the 
intestine (Figure 5, filled circles). Interestingly, 7 weeks post infection with S. 
mansoni, the expression of BATF2 significantly increased in the liver of infected 
animals, while the expression remained unchanged in the gut of the infected 
(Figure 5, open circles). We therefore concluded that BATF2 expression is 





























Figure 5: BATF2 expression in egg-infested tissues during experimental schistosomiasis. 
(A) BATF2 mRNA expression levels in liver and gut tissues from naïve (closed circles) and S. 
mansoni infected (open circles) mice measured using qPCR normalised to HPRT mRNA control. 
(B) Quantification of egg burden the liver and gut of WT (black bar) and BATF2 deficient (white 
bar) mice. The data presented included a sample size of n= 8 - 10 mice per group. *p< 0.05, **p< 
0.01, and ***p<0.001 vs non-infected using one tailed student’s t-test. 
 
 
3.2. No major physiological impairment in BATF2 deficient mice at 
homeostasis, despite a minimal disturbance of immune cell distributions. 
 
To interrogate the need for BATF2 expression in the liver and gut during 
experimental schistosomiasis, we made use of a murine BATF2 deficient 
129SvEv mouse model. The removal of BATF2 expression in these mice was 
confirmed through PCR using the following primers: BATF2 P1 (5'-ACC CTC 
CAC CAT CCT TCT TC), BATF2 P2 (5'- GAC TGG TCT GCA GTG TGA GC), 
BATF2 P3 (5'- CCA GCT CAT TCC TCC CAC T). The BATF2 P1 and P3 primers 
were used to identify the presence of an intact functional BATF2 gene while 
BATF2 P1 and P3 were used to identify the truncated non-functional BATF2 
gene. As shown in figure 6 BATF2 deficient mice had a non-functional truncated 









The body (Figure 7A) and organ weights (Figure 7B) which included liver, spleen 
and heart of the 129SvEv WT and BATF2 deficient (BATF2-/-) mice were 
compared to identify any physiological impairment of the mice in the absence of 
BATF2 expression. The intestinal length was also measured from the stomach 
to the caecum (Figure 7C). Although most of the organs were not affected, the 
intestinal length (from stomach to caecum) was reduced indicating a possible 
role of BATF2 in maintaining the integrity of this tissue. 
 
 
Figure 7. The absence of BATF2 results in reduced intestinal length with no effect on body 
and organ weights at homeostasis. (A) Summary of body and (B) organ weights in relation to 
body weight. (C) Quantification of intestinal length (from base of stomach to caecum). The data 
presented included a sample size of n= 8 - 10 mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 






The organs from the BATF2 deficient mice were further analysed for any signs 
of hepatoxicity by measuring serum levels of alanine transaminase (ALT) and 
aspartate transaminase (AST) (Figure 8). We noted no elevation of liver enzyme 
levels in the sera of BATF2 deficient mice when compared to the littermate 










Figure 8. The absence of BATF2 does not majorly affect tissue damage at homeostasis. 
Quantification of serum levels of alanine transaminase (ALT) and aspartate transaminase (AST) 
in WT (black bars) and BATF2 deficient (white bars) mice. The data presented is from two 
independent experiments which included a sample size of n= 8 - 10 mice per group. *p< 0.05, 
**p< 0.01, and ***p<0.001 vs WT using one tailed student’s t-test.  
 
 
Furthermore, BATF2-deficient mice were analysed for any cellular impairment at 
homeostasis. The cellularities of thymus, spleen, mesenteric lymph nodes and 
guts were defined (Figure 9). In as much as we noted a minimal reduction in total 
mesenteric lymph node cell numbers in BATF2-deficient mice (Figure 9), no 
major alteration of the total cell numbers was observed overall in other analysed 















Figure 9. The absence of BATF2 had no major influence on the organ cellularity in 129SvEv 
mice at homeostasis. Organ cellularities between WT and BATF2 deficient mice. The data 
presented included a sample size of n= 8 - 10 mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 
vs WT using one tailed student’s t-test. 
 
 
 An in-depth analysis of the cell type distribution in the thymus, spleens, MLNs 
and guts of BATF2 deficient mice was then conducted to further assess the effect 
of BATF2 deficiency on immune cell distribution at homeostasis. Single cell 
suspensions were obtained from each of the organs and were analysed by Flow 
cytometry to identify immune cell populations. Figure 10 shows the gating 





Figure 10. Gating strategy used from flow cytometry to identify and quantify lymphocytes 
and myeloid cells. (1) The cells are first gated out from the singlets and (2) single cells to rule 
out doublet cell populations and those with disproportional sizes. (3) Live cells were then gated 
on 7AAD negative population with (4) lymphocytes being identified from FSC-A high and SSC-A 
low. From the lymphocytes, (5) T cell (CD3+ CD19-) and B cell (CD19+ CD3-) lymphocytes were 
gated out and further characterised into (6) DN (CD4- CD8-), SP4 (CD4+ CD8-), DP (CD4+ 
CD8+), and SP8 (CD4- CD8+) in the case of thymus. (7) In MLN, spleen, and gut the T cells were 
further characterised into CD4+ and CD8+ T cells. (8) Myeloid cells were identified as SSC-A 
high and CD45+ gated from the 7AAD- population. From the myeloid population, (9) CD11b+ 
population was gated on in order to identify (10) macrophages (CD11b+ F4/80+), (11) neutrophils 
(CD11b+ Ly6G+), and (12) eosinophils (CD11b+ Siglec-F+). Another population that was gated 
from the myeloid population was the (13) CD11c+ population which represents the majority of 
dendritic cells. From this CD11c+ population the (14) dendritic cells (CD11c+ F4/80-) were gated. 
Two subtype populations of the dendritic cells were further identified within the DC population, 
namely (15) CD11b+ CD11c+ DCs and (16) CD8+ CD11c+ DCs.  
 
 
As depicted in Figure 11   below, the frequencies of lymphocyte and myeloid cell 
populations in thymus MLN, spleen, and the intestinal tissue in wild type and 




BATF2 resulted in a reduced frequency of double negative (CD4- CD8-) 
immature thymocytes which, counterintuitively, did not affect the frequencies of 
DP and SP thymocytes (Figure 11A), or the overall number of thymocytes (Figure 
11A). In the case of the mesenteric lymph nodes (Figure 11B), we noted no 
alteration of the frequencies of the analysed T cell, macrophages or neutrophils 
in BATF2 deficient mice at homeostasis (Figure 11B). However, a reduction of 
CD8+ and CD11b+ dendritic cells was apparent in BATF2 deficient mice (Figure 
11B). Conversely, T cells were less represented in the spleens and guts of 
BATF2 deficient mice (Figure 11C and Figure 11D).  We also noted that the 
frequencies of splenic and intestinal neutrophils and intestinal macrophages 
were altered in BATF2 deficient mice (Figure 11C and Figure 11D). Together, 
our data argue for a possible regulatory role of BATF2 in regulating major 




Figure 11. BATF2 deficiency on cell distribution at homeostasis.  Frequencies of lymphocyte 
(CD3+ CD4+ T cells, CD3+ CD8+ T cells) and myeloid (CD11c+ F4/80- CD8+ DCs, CD11c+ 




populations in  (A) thymus, (B) MLN, (C)  spleen, and (D ) intestinal tissue per group using Flow 
cytometry. The data presented is from two independent experiments which included a sample 




We then questioned whether such altered immune cell distribution – mostly 
apparent in the gut tissue - might translate into an altered tissue immune 
response at homeostasis in the absence of BATF2. To address this, gut tissue 
specific cytokine concentrations were measured. .  As shown in figure 12, the 
absence of BATF2 resulted in an elevated production of various cytokines (IL-1, 
IL-4, IL-5, IL-17, TNF-alpha, and TGF-beta) in the gut tissue (Figures 12). This 
indicated, unprecedentedly, that BATF2 Does play a negative regulatory role on 









Figure 12. Increased cytokine production in the absence of BATF2 at homeostasis in the 




ELISA. The data presented included a sample size of n= 8 mice per group. *p< 0.05, **p< 0.01, 
and ***p<0.001 vs WT using one tailed student’s t-test.). 
 
 
We then addressed whether such elevated tissue cytokines would result in 
increased pathology. For this, we measured the hydroxyproline levels in the liver 
and intestinal tissue to indirectly assess the collagen content and fibrosis in the 
tissues (Figure 13). We noted no change at baseline of the levels of fibrosis in 
the liver and gut of naïve BATF2-deficient mice and littermate control. This 










Figure 13.  The absence of BATF2 had no significant influence on collagen content and 
thus tissue fibrosis at homeostasis. Quantification of hydroxyproline levels, as measures of 
collagen content and fibrosis in liver and intestinal tissues of WT (black bar) and BATF2 deficient 
mice (white bar). The data presented is from two independent experiments which included a 
sample size of n= 8 - 10 mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 vs WT using one 
tailed student’s t-test. 
 
 
Finally, given such changes in the cellular distribution within organs of BATF2 
deficient mice, which failed nonetheless to translate into heightened gut fibrosis 
when compared to littermate controls led us to question whether BATF2 
deficiency might translate into an overall altered immune activation status in 
these mice. To address this, we measured total serum cytokine (Figure 14A, C, 
and D) and IgE levels (Figure 14B) and noted no difference between BATF2-
deficient mice and littermate control serum cytokine levels (Figure 14A, C, and 




the thymus, spleens, MLNs and guts of BATF2-deficient mice, no systemic 

















Figure 14. The absence of BATF2 does not affect serum cytokines and IgE levels at 
homeostasis. Quantification of serum cytokine and antibody concentrations at homeostasis 
using ELISA. The data presented included a sample size of n= 6 - 10 mice per group. *p< 0.05, 
**p< 0.01, and ***p<0.001 vs WT using one tailed student’s t-test. 
 
Overall, our data indicate that BATF2 deficiency at homeostasis does neither 
alter the animals’ body weight nor the integrity of the liver, spleen, heart and gut 





3.3. Increased pro-fibrotic immune response in the gut of S. mansoni-
infected BATF2 deficient mice. 
 
Given that the BATF2 expression was confirmed in both the liver and the intestine 
during acute schistosomiasis. We then sort to understand what role the BATF2 
could be playing in these tissues during acute schistosomiasis. BATF2 deficient 
mice and littermate controls were percutaneously infected with a dose of 80 live 
S. mansoni cercariae and culled for analysis 7 weeks post infection. Liver and 
gut tissues were the focus of our analysis as S. mansoni eggs reside in these 
tissues. 
 
We first analysed immune cell dynamics as a result of S. mansoni infection in 
BATF2 deficient mice (Figure 15). We noted that S. mansoni infection led to a 
significant reduction of T cells in the liver of BATF2 deficient mice when 
compared to S. mansoni infected littermate controls. Of note, however, a 
reduction of macrophages and eosinophils paralleled by a considerable 
expansion of CD8+ DCs and T cells (both CD4+ and CD8+) was observed in the 
gut of S. mansoni-infected BATF2 deficient mice (Figure 15B). 
    
 
Figure 15. Immune cells distribution in the liver and the intestinal tissue of BATF2 deficient 
mice during schistosomiasis. Frequencies of lymphocyte (CD3+ CD4+ T cells, CD3+ CD8+ T 
cells) and myeloid (CD11c+ CD8+ DCs, CD11c+ CD11b+ DCs, CD11b+ F4/80+ macrophages, 
Ly6G+ neutrophils, Siglec-F+ eosinophils) populations in liver (A) and intestinal tissue (B) using 
Flow cytometry. The data presented included a sample size of n= 8 mice per group. *p< 0.05, 




T-cells are instrumental in defining the immune properties thus pathological 
course of schistosomiasis. To address the functional nature of the expanded T 
cells in the parasitized tissues of S. mansoni-infected BATF2 deficient mice, we 
further performed intracellular cytokine detection (Figure 16). Whereas a drastic 
reduction of cytokine production was noted in liver CD4+ T cells from S. mansoni-
infected BATF2 deficient mice when compared to infected littermate control liver 
CD4+ T cells (Figure 16A), gut CD4+ T-cells from S. mansoni-infected BATF2 
deficient mice display a robustly elevated production of pro-fibrotic cytokines i.e. 
IL-5, IL-13 and IL-17 but not IL-4 when compared to gut CD4+ T cells from 
littermate controls (Figure 16B).  
 
 
Figure 16. Increased pro-fibrotic CD4+ T cells in the gut while reduced in the liver. 
Frequency of cytokine producing CD4+ T cells from single cell suspension if liver (A) and intestine 
(B). The data presented included a sample size of n= 8 mice per group. *p< 0.05, **p< 0.01, and 
***p<0.001 vs WT using one tailed student’s t-test 
 
 
Interestingly the profile was similar for CD8+ T cells where an increased 
production of pro-fibrotic cytokines (IL-5, IL-13, IL-17) was apparent in the gut of 
S. mansoni-infected BATF2 deficient mice when compared to Gut CD8+ T cells 






Figure 17.  Increased pro-fibrotic CD8+ T cells in the gut. Frequency of cytokine producing 
CD8+ T cells from single cell suspension if liver (A) and intestine (B). The data presented included 
a sample size of n= 8 mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 vs WT using one tailed 
student’s t-test.  
 
 
Altogether our findings demonstrate that BATF2 deficiency during 
schistosomiasis leads to an expansion of pro-fibrotic cytokine-producing T cells 
in the gut but not the liver in S. mansoni-infected BATF2 deficient mice.  
 
We looked deeper on our observations and assessed the levels of liver and gut 
tissue cytokines. Besides, IL-5 which was increased in the liver of S. mansoni-
infected BATF2 deficient mice when compared to littermate controls (Figure 
18A), gut tissues from S. mansoni-infected BATF2 deficient mice showed a 
massive elevation in the production of TNF-alpha, IL-5, IL-13, TGF-beta and IL-
17 all pro-fibrotic cytokines and pro-inflammatory IFN-gamma (Figure 18B). This 
observation reconciles with our intracellular cytokine profile in the gut of S. 
mansoni-infected BATF2 deficient mice and further suggests the elicitation of a 
strongly pro-fibrotic response specifically in the gut, but not the liver, of S. 




































Figure 18. Increased pro-fibrotic and inflammatory cytokine profiles in the intestine in 
BATF2 deficient mice. Quantification of (A) liver and (B) intestinal cytokines using ELISA in WT 
(black bars) and BATF2 deficient mice (white bars). The data presented included a sample size 








3.4. Increased fibro-granulomatous inflammation in the gut of S. mansoni-
infected BATF2 deficient mice. 
 
Previous studies have shown that the development of extreme Th1, Th2, or Th17 
cytokine producing phenotypes are highly detrimental during Schistosomiasis 
(Hoffman, 200; Rutitzky, 2007; Hammerich, 2010). The current study further 
aimed to understand how this observed increase in Th1, Th2, and Th17 
responses continued to the gut would influence the egg-induced 
immunopathology in S. mansoni-infected BATF2 deficient mice. 
 
First, the organ weights (spleen, heart and liver) of S. mansoni-infected BATF2-
deficient mice were measured and compared to those of infected littermate 
controls (Figure 19). No significant differences in the organ weights were noted 
between S. mansoni-infected BATF2 deficient mice and those of the infected 
littermate controls (Figure 19).   
 
Figure 19. Organ weight in BATF2-deficient mice during schistosomiasis. Quantification 
of spleen (A), heart (A) and liver (D) weight. The data presented included a sample size of n 
= 10 mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 vs WT using one tailed student’s t-test. 
 
 
To further appraise the pathology, Haematoxilin & Eosin staining of liver sections 
from S. mansoni-infected BATF2 deficient mice were analysed. We noted no 
noticeable significant alterations in the granuloma structure when compared with 
the wild type mice (Figure 20A). The area of the granuloma surrounding the S. 
mansoni egg, an indicator of the level of granulomatous inflammation was not 
affected in S. mansoni-infected BATF2 deficient mice when compared to infected 
littermate controls as determined by computational analysis on an automated 











Figure 20. Absence of BATF2 does not affect the development of egg-surrounding 
granuloma in liver. Representative H&E staining of liver sections for morphological analysis of 
the tissue, and (F) quantification of granuloma area around each egg lodged in the tissue. 100 
granulomas per group were included in the analysis.  The data presented included a sample size 




We further stained liver sections with Chromotrope aniline blue (CAB) to assess 
the degree of fibrosis around the eggs logged in the liver tissue (Figure 21A).  As 
shown in figure 21A, the blue staining intensity, representing collagen was 
reduced in liver sections of S. mansoni-infected BATF2 deficient mice when 
compared to liver sections from infected littermate controls. This was confirmed 
by measuring hydroxyproline levels in liver tissues (Figure 21B) showing reduced 
hydroxyproline levels in the liver tissue of S. mansoni-infected BATF2 deficient 
mice when compared to the levels reported from liver tissues from infected 





   
 
 
Figure 21. Liver fibrosis in BATF2-deficient mice during schistosomiasis. Representative 
CAB staining and (H) quantification of hydroxyproline levels normalised to egg numbers, as a 
measures of collagen content and fibrosis in liver. The data presented included a sample size of 
n = 8 - 10 mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 vs WT using one tailed student’s 
t-test. 
 
Lastly, to assess hepatic pathology in our model, the hepatocellular damage was 
also measured by determining the serum levels of alanine transaminase (ALT) 
and aspartate transaminase (AST).  Whereas the AST levels were not affected 
(Figure 22), the ALT levels were reduced strongly arguing against hepatotoxicity 
as a pathological feature ascribable to S. mansoni-infected BATF2 deficient mice 












Figure 22. Reduced liver enzyme in BATF2 deficient mice during acute schistosomiasis. 
Analysis of hepatocellular damage measured by serum ratios of alanine transaminase (ALT) and 
aspartate transaminase (AST) The data presented included a sample size of n= 8 - 10 mice per 




Next, the gut immunopathology was analysed. First the intestinal tissue length 
was measured as an indicator of the alteration of the gut function (Weaver, 1991). 
When comparing S. mansoni-infected BATF2 deficient mice to infected littermate 
controls, we noted an increased intestinal (Figure 23A) and colonic length (Figure 





















Figure 23. Increased intestinal and colon length in BATF2 deficient mice during acute 
schistosomiasis. Representative (A) and quantification of (B) intestinal length (from base of 
stomach to caecum) and (C) colon length. The data presented included a sample size of n= 10 
mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 vs WT using one tailed student’s t-test. 
 
 
To substantiate such an observation, the total gut cellularity was determined 
(Figure 24). We reported a strong trend of increased total gut cells in S. mansoni-
infected BATF2 deficient mice further supporting the increased gut length 












Figure 24. Intestinal cellularity in BATF2 deficient mice during schistosomiasis. 
Quantification of gut cellularity between wild type and BATF2 deficient mice. The data presented 
included a sample size of n= 8 mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 vs WT using 
one tailed student’s t-test. 
 
 
Furthermore, H&E staining showed more cellular infiltration around the eggs of 
S. mansoni parasites in the gut of S. mansoni-infected BATF2 deficient mice 









Figure 25. Increased cellular infiltration around S. mansoni eggs in BATF2 deficient mice. 
Representative H&E staining of gut sections for morphological analysis of the tissue.  
 
Finally, fibrosis was assessed in the gut of S. mansoni-infected BATF2 deficient 
mice when compared to infected littermate controls (Figure 26). A representative 
CAB staining shows an increased fibrosis around the area surrounding the S. 
mansoni eggs (Figure 26A), and this was confirmed by hydroxyproline levels in 
the tissue, which were considerably elevated in the gut of S. mansoni-infected 





Taken together, our data indicates a heightened fibrogranulomatous 
inflammation and ensuing elevated fibrosis in the gut, but not the liver, of BATF2 






Figure 26. Increased fibrosis in BATF2 deficient mice during acute schistosomiasis. 
Representative CAB staining (A) for analysis of collagen content, and quantification of 
hydroxyproline levels (B) normalised to egg number to measure gut fibrosis. The data presented 
included a sample size of n= 8 mice per group. *p< 0.05, **p< 0.01, and ***p<0.001 vs WT using 











3.5. BATF2 deficiency results in increased susceptibility of S. mansoni-
infected mice during experimental acute schistosomiasis. 
 
With reduced immunopathology in the liver and increased immunopathology in 
the intestine, we then aimed to further understand how this would affect the 
susceptibility of S. mansoni-infected BATF2 deficient mice when compared to 
infected littermate controls. To address this, both the wild type and BATF2 
deficient mice were infected percutaneously with a dose of 80 live S. mansoni 
cercariae and monitored until the attainment of an ethically defined humane 
endpoint (persistent bloody diarrhoea, severe lethargy, weight loss of 20% or 
more). We noted that BATF2 deficient mice began to rapidly and prematurely 
drop in weight from week 8 post infection (Figure 27A). This rapid weight loss 
was accompanied by severe lethargy resulting in extensive premature mortality 
of S. mansoni-infected BATF2 deficient mice that all succumbed 12 weeks post 
infection leaving more than 50% of surviving S. mansoni-infected littermate 
controls (Figure 27B).    Therefore, BATF2 deficiency renders mice considerably 
more susceptible to S. mansoni infection indicating a protective role for this 
transcription factor in the host survival during schistosomiasis, thus the initially 

































Figure 27. BATF2 is required for survival during S. mansoni infection. (A) Body weight 
change was measured weekly during the onset of infection. (B) Survival curve of Wild type (WT) 
and BATF2-/- mice. The data presented included a sample size of n= 8 - 10 mice per group. *p< 
0.05, **p< 0.01, and ***p<0.001 vs WT using one tailed Chi square (Gehan-Breslow Wilcoxon 












4. Discussion, conclusion and future work 
 
Schistosomiasis is one of the tropically neglected diseases with the potential to 
cause morbidity and mortality in infected populations unless well controlled. 
Individuals or mice infected with S. mansoni usually develop liver and intestinal 
associated pathology that is characterised by the development of protective 
granulomas around the eggs lodged in the tissues and ultimately results in 
extensive egg-induced fibrosis. Both the granuloma formation and fibrosis are 
mediated by the host immune response during the infection, which include the 
moderate Th1 response to parasite antigens, and the dominant Th2 and Th17 
responses to the egg-derived antigens (Wilson, 2007; Hams, 2013). Mechanisms 
which control the Th1, Th2, and Th17 cells are necessary to prevent severe 
tissue pathology (Wilson, 2007). In this study we propose a potentially important 
transcription factor called BATF2 which has the ability to control Th1, Th2, and 
Th17 linked fibrogranulomatous immunopathology in the intestine during 
experimental schistosomiasis. 
 
Our work first confirmed the expression of BATF2 in liver and intestinal tissues 
at homeostasis and identified the potential effect of removing this transcription 
factor from the 129SvEv mice. Removal of the transcription factor did not affects 
most of the organs including the liver which showed no alteration in weight, tissue 
damage (ALT and AST levels), and or development of fibrosis in the tissue. This 
therefore, indicated that BATF2 expression might be dispensable to maintain 
liver homeostasis. However, in the case of the gut, a reduced length in the 
absence of BATF2 was observed pointing at a possible heightened inflammation 
in the gut of BATF2 deficient mice at homeostasis, consistent with reports linking 
reduced gut length and inflammation (Puapong 2006). In fact, we then noted an 
increase in pro-inflammatory type 1 (TNF-alpha), type 2 (IL-4, IL-5) and type 17 
(IL-17) cytokine levels in the gut of BATF2 deficient mice at steady state. The 
effects of such an increased cytokine release were, however, not clinically 
relevant as no sign of pathology could be observed in BATF2 -deficient mice at 
homeostasis. In fact, despite the altered cellular distribution in several organs, 




enzyme and cytokine levels as well as tissue fibrosis levels remained unchanged 
in BATF2 deficient mice at homeostasis. The observation of such subtle, albeit 
clinically inconsequent, changes observed in BATF2 deficient mice at 
homeostasis suggest a hitherto superficially understood role for this transcription 
factor in the gut homeostasis, particularly. Further experiments are clearly 
needed at this stage to address such subtleties. A possible way forwards could 
be the observation of inflammation control in the gut of aging BATF2 mice. More 
insights on the clear but so far clinically unapparent role of BATF2 in regulating 
pathology at homeostasis as per our present findings, should benefit from such 
an experiment. Several model of aging mice, have been used to unveil the role 
of host factors that reveal no clinical relevance in young mice at homeostasis 
(Wohlfert et al., 2011; Rudra et al., 2012), given the pervasive feature of aging 
tissues to display enhanced inflammation.  
 
In this work, inflammation was brought in the form of schistosomiasis infection. 
In this setting, we first noted that BATF2 expression in the liver and the intestinal 
tissue was not reduced in response to acute schistosomiasis. Interestingly, the 
expression of BATF2 was elevated in the liver while in the intestine, it was 
maintained. This is rather intriguing, given the overall tendency of host factors to 
be considerably downregulated in the liver and gut tissues during murine 
schistosomiasis (Harvie, 2007; Manivannan, 2010). The fact that BATF2 
escapes such a pattern of downregulation and has a maintained/increased tissue 
expression following S. mansoni infection further argues for a critical role of this 
factor during the disease. Possible avenues for explanation of such a need would 
be that i) BATF2 is a parasite-driven host factor meant to aid the parasite 
establishment in the host. Our own observation of a similar egg burden, thus 
parasite fitness in the livers and guts of S. mansoni-infected BATF2 deficient 
mice when compared to infected littermate controls strongly argues against this 
hypothesis. One could therefore rather consider that ii) the host expresses this 
factor in order to limit tissue pathology during schistosomiasis and preserve 
tissue integrity for survival.      
 
In fact, we noted that BATF2 deficiency led to a massive expansion/recruitment 




infected BATF2 deficient mice when compared to infected littermate controls 
supporting a negative regulatory role of BATF2 in gut inflammation during 
schistosomiasis. Strikingly, the pro-fibrotic nature of the cytokines abundantly 
released by gut T-cells in S. mansoni-infected BATF2 deficient mice when 
compared to infected littermate controls supports the role suggested for BATF2 
in gut homeostasis in naïve mice. Importantly, given the pathological nature of 
schistosomiasis on the host gut, the consequences of BATF2 deficiency 
observed in naïve mice were exponentially worsened leading to aggravated gut 
fibrosis and granulomatous inflammation. Although it may seem confounding to 
have aggravated gut fibrosis in the presence of increased anti-fibrotic cytokine 
(IFNƴ), the high ratio of IL-13 to IFNƴ shown in figure 8, stands to reason for the 
observed pathology as previously demonstrated (Chiaramonte, 2003). It is 
therefore tempting and stands to reason to conclude here, overall, that BATF2 is 
critical for gut homeostasis even in naïve mice and in so doing constitutes a 
critical actor in the host ability to mitigate untoward gut fibrogranulomatous 
inflammation and pathological fibrosis during schistosomiasis. In fact, the 
premature wasting disease observed during schistosomiasis and the ensuing 
premature death in BATF2 deficient mice is quite indicative of uncontrolled gut 
pathology. In as much as we did not note gut bleeding as reported for other 
susceptible murine models (Herbert, 2004), the severe wasting disease suggests 
a compromised ability of the animals to feed thus possible enteropathy.  
 
It is quite interesting that the frequencies of CD8+ dendritic cells were elevated 
in the gut of S. mansoni-infected BATF2 deficient mice when compared to 
infected littermate controls and that this most likely mediate the observed 
increase of Gut T cells observed. It could prove informative at this point to see if 
CD8 blockade would rescue the observed physical degradation in S. mansoni-
infected BATF2 deficient mice when compared to infected littermate controls. 
Experiments aiming at addressing this point are currently underway and should 
shed more mechanistic insights on what the underlying bases of the susceptibility 
of S. mansoni-infected BATF2 deficient mice when compared to infected 
littermate controls are / might be. Moreover, the intestinal nature of the reported 
exacerbated pathology in S. mansoni-infected BATF2 deficient mice when 




microbiome in the observed susceptibility of BATF2 deficient mice during 
schistosomiasis. Further tests on the animal gut microbial profile before and after 
schistosomiasis are also currently underway. With regard to the latter, co-
housing experiments between S. mansoni-infected BATF2 deficient mice and S. 
mansoni-infected littermate controls have also been set. Whether BATF2 
deficiency alter the gut fitness in a microbiome-dependent or independent 
manner should be uncovered by these experiments. As of yet, however, our 
findings clearly and unambiguously indicate that BATF2 deficiency compromises 
the host ability to control gut pathology and this is fatally exacerbated during 
schistosomiasis. 
 
A rather puzzling observation in our work was the absence of heightened liver 
pathology in S. mansoni-infected BATF2 deficient mice when compared to 
infected littermate controls. In fact, the upregulation of BATF2 expression in the 
liver, rather than the sustained expression in the gut, would have suggested a 
more deleterious effect of BATF2 deficiency on the liver when compared to the 
gut. We noted, however, an amelioration of the hepatic parameters of S. 
mansoni-infected BATF2 deficient mice when compared to infected littermate 
controls i.e. reduced serum liver enzymes, reduced frequencies of liver T cells 
and reduced levels of liver fibrosis amid a maintained granulomatous response. 
This most likely defines a tissue-specific modus operandi for BATF2 where the 
expression in the liver promotes liver fibrosis and the expression in the gut refrain 
liver fibrosis. This theory of an organ specific and contradictory role for BATF2 
during experimental schistosomiasis is further supported by our cellular and 
cytokinic profile in S. mansoni-infected BATF2 deficient mice when compared to 
infected littermate controls. In fact, whereas frequencies of CD8+ DCs are 
increased in the gut of S. mansoni-infected BATF2 deficient mice when 
compared to infected littermate controls, their frequency in the liver of S. 
mansoni-infected BATF2 deficient mice when compared to infected littermate 
controls is reduced. This parallels a cascade of antagonisms between the gut 
and the liver (High T cells and fibrosis in Gut vs low T cells and fibrosis in liver). 
What processes regulate the context-dependent function of BATF2 cannot be 
addressed with our present data. A possible way forward in trying to answer such 




Another possible explanation for the dual roles observed for BATF2 might 
resides in the established mechanistic feature of the factor itself. In fact, BATF2 
only functions with binding partner(s) (Roy, 2015; Murphy, 2013). Such binding 
partners might be tissue-dependent and as such provide a mechanistic 
explanation for the apparently opposing role of BATF2 in the liver and gut. Since 
BATF2 lacks the DNA binding motif and usually mediate its function by binding 
with other transcription factors that have the DNA binding motif, we believe the 
function of the BATF2 will depend on the type of transcription factor it forms 
heterodimer with (Murphy, 2013). Therefore, more studies will need to be carried 
out to identify BATF2 binding partners which could potentially explain the 
differences observed in the liver as well as the intestinal tissue. This would also 
set a proof of principle to test the role of BATF2 in other organs and upon different 
infectious states. These endeavours would greatly not only from cell-specific but 
also tissue-specific BATF2 deficient mice. 
 
In conclusion, our data indicate an unprecedented tissue-specific expression and 
role for BATF2 in regulating tissue inflammation, and fibroproliferative 
inflammation in health and schistosomiasis disease whereby an overall host 
protective role is defined for BATF2 expression in countering the excessive 
expansion of CD8+ DCs, CD4+ and CD8+ T cells in the gut of schistosomiasis-
diseased mice therefore minimizing fibrogranulomatous inflammation and the 
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